Oxford Biomedica (LON:OXB) Hits New 12-Month High - Here's What Happened

Key Points

• Oxford Biomedica's share price reached a new 52-week high of GBX 600 ($8.12), closing at GBX 594.75 ($8.05) with a trading volume of 65,561 shares.
• The company's market capitalization stands at £718.68 million, and it has a consensus rating of "Moderate Buy" with a consensus target price of GBX 540.25.
• Recent insider transactions included the sale of 4,563 shares by Dame Kay Davies and the purchase of 11,389 shares by Heather Preston, indicating activity among company insiders.

Oxford Biomedica plc (LON:OXB - Get Free Report) hit a new 52-week high on Wednesday . The company traded as high as GBX 600 ($8.14) and last traded at GBX 594.75 ($8.06), with a volume of 65561 shares traded. The stock had previously closed at GBX 593 ($8.04).

Analysts Set New Price Targets

A number of brokerages recently weighed in on OXB. Royal Bank Of Canada boosted their price objective on shares of Oxford Biomedica from GBX 800 to GBX 930 and gave the stock an "outperform" rating in a report on Tuesday, August 26th. Peel Hunt reaffirmed a "buy" rating and issued a GBX 451 target price on shares of Oxford Biomedica in a research report on Friday, August 1st. Finally, JPMorgan Chase & Co. cut their target price on shares of Oxford Biomedica from GBX 490 to GBX 400 and set a "neutral" rating for the company in a research report on Tuesday, July 15th. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of GBX 540.25.

Oxford Biomedica Stock Performance

The business's 50-day moving average price is GBX 467.68 and its 200-day moving average price is GBX 360.13. The company has a debt-to-equity ratio of 166.48, a quick ratio of 1.67 and a current ratio of 2.35. The stock has a market cap of £712.67 million, a P/E ratio of -1,420.36 and a beta of 1.09.

Insider Activity at Oxford Biomedica

In other news, insider Heather Preston bought 11,389 shares of the stock in a transaction that occurred on Tuesday, June 17th. The shares were bought at an average price of GBX 324 per share, for a total transaction of £36,900.36. Also, insider Roch Doliveux bought 67,000 shares of the stock in a transaction that occurred on Friday, August 15th. The shares were purchased at an average price of GBX 450 per share, for a total transaction of £301,500. 43.30% of the stock is owned by corporate insiders.

Oxford Biomedica Company Profile

Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.